Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | FEN1 | P39748 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743069 | 0.87 | KIF11 (0.65) | KIF11PTGS2PTGS1ALOX5APFEN1 | |
| SCHEMBL1888623 | 0.82 | FEN1 (0.46) | KIF11ALOX5APFEN1 | |
| SCHEMBL1885330 | 0.79 | L3MBTL1 (0.46) | KIF11ALOX5APFEN1 | |
| SCHEMBL1656041 | 0.77 | ALOX5AP (0.49) | KIF11PTGS2PTGS1ALOX5APFEN1 | |
| SCHEMBL6732105 | 0.77 | KIF11 (0.72) | KIF11PTGS2PTGS1 | |
| SCHEMBL1886802 | 0.76 | MPL (0.46) | KIF11ALOX5APFEN1 | |
| SCHEMBL1892790 | 0.72 | AHR (0.42) | KIF11ALOX5APFEN1CA12CA1 | |
| SCHEMBL4263174 | 0.72 | PTGS2 (0.72) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL6733336 | 0.72 | PTGS2 (0.67) | KIF11PTGS2PTGS1CA12CA1 | |
| SCHEMBL6725503 | 0.71 | PTGS2 (0.61) | KIF11PTGS2PTGS1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | claimed |
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA3, CHRM3 | KIF11 3624/4885PTGS2 2679/4885PTGS1 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.